Sara Lodi
Profiles

Sara Lodi, PhD

Associate Professor, Biostatistics - Boston University School of Public Health

617-358-2705
slodi@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Sara Lodi is an Associate Professor of Biostatistics at the Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on causal inference methods for observational studies using big data, methods for causal inference to improve the statistical analysis of clinical trials, and the reconciliation of results from clinical trials and observational studies. She leads cutting edge research that focuses on the translation of methodologic advancements in causal inference into actionable findings for real world public health research questions, mainly in the areas of infectious diseases (HIV, hepatitis C, tuberculosis) and substance use disorder. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL, and HepCAUSAL collaborations. She’s been an instructor for both BS851 Applied Statistics in Clinical Trials and BS807 Applied Causal Inference in Health Research.

Education

  • London School of Hygiene & Tropical Medicine, PhD Field of Study: Statistics
  • University of Southampton, MSc Field of Study: Statistics
  • Univ of Bologna, BA Field of Study: Statistics

Websites

Classes Taught

  • SPHBS807
  • SPHBS851

Publications

  • Published on 9/23/2025

    Cashin AG, Hansford HJ, Hernán MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH. Transparent Reporting of Observational Studies Emulating a Target Trial-The TARGET Statement. JAMA. 2025 Sep 23; 334(12):1084-1093. PMID: 40899949.

     Read At: PubMed
  • Published on 9/22/2025

    Degirmenci HB, Peloquin CE, Westerland M, Lodi S, Machado PM, Jafarzadeh SR, Neogi T, Gensler LS, Dubreuil M, Liew JW. Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2025 Sep 22. PMID: 40977482.

     Read At: PubMed
  • Published on 9/4/2025

    Weinstein ZM, Magane KM, Lodi S, Doeleman D, Ventura AS, Bazzi AR, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. Associations between COVID impact domains and time to buprenorphine treatment disengagement. Am J Drug Alcohol Abuse. 2025 Sep 04; 1-10. PMID: 40906491.

     Read At: PubMed
  • Published on 9/3/2025

    Cashin AG, Hansford HJ, Hernán MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH. Transparent reporting of observational studies emulating a target trial: the TARGET Statement. BMJ. 2025 Sep 03; 390:e087179. PMID: 40903028.

     Read At: PubMed
  • Published on 3/19/2025

    Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645. PMID: 40104887.

     Read At: PubMed
  • Published on 2/18/2025

    Chalouni M, Van Santen DK, Berenguer J, Jarrin I, Miro JM, Klein MB, Young J, Torgersen J, Rentsch CT, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Rauch A, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Hernán MA, Lodi S. Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virus. AIDS. 2025 Jul 01; 39(8):1074-1079. PMID: 39970192.

     Read At: PubMed
  • Published on 1/8/2025

    Muyindike WR, Fatch R, Lodi S, Emenyonu NI, Kekibiina A, Adong J, Beesiga B, Marson K, Thirumurthy H, McDonell MG, Kamya MR, Chamie G, Hahn JA. Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial. EClinicalMedicine. 2025 Feb; 80:103045. PMID: 39867970.

     Read At: PubMed
  • Published on 12/17/2024

    Biondi BE, Munroe S, Lavarin C, Curtis MR, Buzzee B, Lodi S, Epstein RL. Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder. Clin Infect Dis. 2024 Dec 17; 79(6):1428-1436. PMID: 39356149.

     Read At: PubMed
  • Published on 12/16/2024

    da Costa ECM, Silva DP, Lodi S, Simões DA, Godoy BS. The Effect of Climatic Conditions on the Seasonality of Pest Insect Populations in Eucalyptus Plantations in the Neotropics. Neotrop Entomol. 2024 Dec 16; 54(1):16. PMID: 39680234.

     Read At: PubMed
  • Published on 8/5/2024

    Weinstein ZM, Magane KM, Lodi S, Ventura AS, Bazzi AR, Blodgett J, Fielman S, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. The Impact of COVID-19 on Substance Use and Related Consequences Among Patients in Office-based Opioid Use Disorder Treatment. J Addict Med. 2025 Jan-Feb 01; 19(1):12-19. PMID: 39101572.

     Read At: PubMed

View 89 more publications:View Full Profile at BUMC

News & In the Media

View all profiles